Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEK162 Combined With Idarubicin and Cytarabine in Relapsed/Refractory RAS-Mutated AML
NCT02049801Phase 1Terminated
- Start
- Dec 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of binimetinib in acute myeloid leukemia (AML). Primary endpoint: Maximum Tolerated Dose at 28 days. Started Dec 2014; status: terminated.
02
Drugs
binimetinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02049801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02049801.